Pharma News, 2024

BeiGene has announced the opening of its new US biologics manufacturing and clinical research and development (R&D) facility at Hopewell, New Jersey. Situated at the Princeton West Innovation ...

A new preclinical model offers a unique platform for studying the Parkinson's disease process and suggests a relatively easy method for detecting the disease in people, according to a new study le...

Fast track designation has been granted by the FDA to the investigational menin and mixed-lineage leukemia (MLL) inhibitor DSP-5336 as a potential treatment for relapsed/refractory acute myelo...

South Korean pharma firm Samsung Bioepis has secured approval from the US Food and Drug Administration (FDA) for Epyscyi (eculizumab-aagh) as a biosimilar to Alexion Pharmaceuticals’...

New findings highlight potential advantages of MIRA's novel oral ketamine analog for treating neurological and neuropsychiatricdisorders

An Israeli treatment for congestive heart failure has been granted Breakthrough Device Designation by the US Food and Drug Administration (FDA).

Postpartum depression (PPD) is largely underdiagnosed and therefore, undertreated.

Pseudomyxoma peritonei is a rare and poorly understood cancer, characterized by the progressive accumulation of mucin in the abdominal cavity.

The 25th International AIDS Conference will be held between 22 and 26 July in Munich, Germany.

Boehringer Ingelheim will sell an unbranded version AbbVie’s reference drug at a 92% discount to gain traction in the Humira (adalimumab) biosimilar market.

The US Food and Drug Administration (FDA) has announced plans to establish a new innovative hub aimed at improving treatment options for rare disease patients.

The US Food and Drug Administration (FDA) has accepted the biologics licence application (BLA) and granted priority review for Pierre Fabre Pharmaceuticals’ Tabelecleucel (Tab-ce...